Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial
Titel:
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial
Auteur:
Borges, Álvaro H Russell, Marisa Tait, Dereck Scriba, Thomas J Nemes, Elisa Skallerup, Per van Brakel, Elana Cabibbe, Andrea M Cirillo, Daniela M Leuvennink-Steyn, Mildie Rutkowski, Kathryn T Wood, Grith K Thierry-Carstensen, Birgit Tingskov, Pernille N Meldgaard, Emilie C Kristiansen, Max P Søndergaard, Rie E Hansen, Christian H Follmann, Frank Jensen, Charlotte G Gela, Anele Ntinginya, Nyanda E Ruhwald, Morten Shenje, Justin White, Lisa Innes, Craig Selepe, Pearl Ngaraguza, Beatrice Holmgren, Chantelle Collings, Tarryn Andersen, Peter Dawson, Rodney Churchyard, Gavin Sabi, Issa Diacon, Andreas H Mortensen, Rasmus Hatherill, Mark